ELEV

Elevation Oncology
ELEV

Overview Fund Activity
Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

25 hedge funds and large institutions have $16.1M invested in Elevation Oncology in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

Holders
25
Holders Change
-2
Holders Change %
-7.41%
% of All Funds
0.43%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
2
Increased
5
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Geode Capital Management
1
Geode Capital Management
Massachusetts
$102K
2
Renaissance Technologies
2
Renaissance Technologies
New York
$326K
3
AC
3
Annandale Capital
Texas
$34K
4
TRCT
4
Tower Research Capital (TRC)
New York
$8K
5
CC
5
Caxton Corporation
New Jersey
$77K

Top Sellers

1
BC
1
Boxer Capital
California
$0
2
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$0
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$376K
4
CAM
4
Cormorant Asset Management
Massachusetts
$2.21M
5
VF
5
Virtu Financial
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
Barclays
26
Barclays
United Kingdom
$0 392 – –
Morgan Stanley
27
Morgan Stanley
New York
$0 115 – –
CFGS
28
Concourse Financial Group Securities
Alabama
– – – –
Wells Fargo
29
Wells Fargo
California
$0 88 +46 +110%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$0 169 +169 New
1
2